RNA vs MDWD

For growth investors, Atrium Therapeutics, Inc.

(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus -16. 1% for MediWound Ltd. (MDWD). Analysts rate MediWound Ltd. (MDWD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Atrium Therapeutics, Inc.

(RNA) delivered a total return of -51. 5%, compared to -56. 4% for MediWound Ltd. (MDWD). Over 10 years, the gap is even starker: RNA returned -55. 3% versus MDWD's -75. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MediWound Ltd.

(MDWD) is the lower-risk stock at 1. 01β versus Atrium Therapeutics, Inc. 's 1. 38β — meaning RNA is approximately 36% more volatile than MDWD relative to the S&P 500. On balance sheet safety, Atrium Therapeutics, Inc. (RNA) carries a lower debt/equity ratio of 2% versus 20% for MediWound Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atrium Therapeutics, Inc.

(RNA) is pulling ahead at 70. 9% versus -16. 1% for MediWound Ltd. (MDWD). On earnings-per-share growth, the picture is similar: MediWound Ltd. grew EPS 30. 7% year-over-year, compared to -55. 0% for Atrium Therapeutics, Inc.. Over a 3-year CAGR, RNA leads at 26. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MediWound Ltd.

(MDWD) is the more profitable company, earning -140. 8% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps -140. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDWD leads at -149. 1% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MediWound Ltd.

(MDWD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01)). Both have compounded well over 10 years (MDWD: -75. 6%, RNA: -55. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RNA is a small-cap high-growth stock; MDWD is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.